More specifically, overexpression of Tpl2 has been shown to drive resistance to Raf inhibition in melanoma (Johannessen et al., 2010; Monsma et al., 2015); however, the role of elevated Tpl2 protein levels in resistance to IM or, more generally, drug resistance in leukemia, has not been explored. This evidence concerns the gene MAP3K8 and melanoma.